

NICE PUBLIC HEALTH PROGRAMME GUIDANCE

Type 2 diabetes: preventing pre-diabetes among adults in high-risk groups

4th meeting of the Programme Development Group Wednesday 26th May 2010

Royal College of Anaesthetists, Red Lion Square, Holborn, London

Attendees:	<p><i>Programme Development Group (PDG) Members:</i> Nick Wareham (Chair), Bennett Quinn, Anne Dornhorst, Jennifer Tringham, Neel Basudev (joined at 11am), Mieria Jofre-Bonet (left at 2pm), Steven Cummins, Margaret Guy, Marie Cummins (left at 2pm), Wasim Hanif, Aderonke Jomo-Coco (left at 3.30pm), Nigel Unwin, Marc Suhrcke, Sarah Wild, Sabina Syed, Ameet Bakhai</p> <p><i>Experts:</i> Alison Tedstone (Food Standards Agency)</p> <p><i>NICE:</i> Catherine Swann, Clare Wohlgemuth, Alastair Fischer, Emma Doohan, Adrienne Cullum, Karen Pelpoe, Ruaraidh Hill,</p> <p><i>Review Team (SchARR) (left at 2pm):</i> Nick Payne, Emma Everson Hock, Alan Brennan, Mike Gillet, Laurence Blake</p> <p><i>Observers:</i> Jane Moore (NICE Implementation)</p>
Apologies:	<p><i>Programme Development Group (PDG) Members:</i> Akeem Ali, Amanda Adler (Co-opted member), Tim Marsh</p>

Agenda Item		Action
1. Welcome and introductions	<p>Apologies were received from Akeem Ali, Amanda Adler and Tim Marsh.</p> <p>Minutes of the last meeting Some minor amendments were agreed to the minutes.</p> <p>Action: Emma to publish minutes on website.</p> <p>Update of actions/matters arising:</p> <ul style="list-style-type: none"> • All of the actions were completed or will be discussed during the meeting. 	Emma Doohan

	<p>Declarations of Interest</p> <p>Personal pecuniary interest Ameet Bakhai Wasim Hanif</p> <p>Personal family interest Ameet Bakhai</p> <p>Non-personal pecuniary interest Sabina Syed Ameet Bakhai Margaret Guy</p> <p>Personal non-pecuniary interest Ameet Bakhai Anne Dornhorst Marie Cummins Wasim Hanif Margaret Guy</p> <p>No new DOIs were made.</p>	
<p>2. Evidence for the guidance (Clare Wohlgemuth)</p>	<p>Clare Wohlgemuth from NICE presented an outline of the evidence presented to the PDG to date and an outline of the evidence and expert testimony which will be presented at the forthcoming PDGs.</p> <p>The PDG were given an opportunity to comment on the suggested approach to the evidence and to suggest any changes.</p> <p>Action point:</p> <ul style="list-style-type: none"> • It was agreed that it was important to cross reference this guidance with other related pieces of diabetes guidance. 	
<p>3. Expert testimony on expert advice, dietary surveys and nutrition research (Alison Tedstone)</p>	<p>Alison Tedstone from the Food Standards Agency provided an outline of the work of the Food Standards Agency, gave an overview of the findings from some of the key nutrition surveys undertaken within the UK, and outlined some of the key findings of dietary interventions on insulin levels.</p> <p>The PDG were given an opportunity to ask any questions or raise any discussion points.</p>	
<p>4. Economic modelling plan (Alan Brennan)</p>	<p>Alan Brennan from SchARR presented an outline of the structure of the economic model for this project.</p> <p>The PDG had a discussion about the different parameters that could be used in the economic model. The committee agreed</p>	

	<p>some of the parameters for the model, and suggested some possible sensitivity analyses which will also need to be undertaken.</p> <p>Action points:</p> <ul style="list-style-type: none"> • It was agreed that the model should be developed according to the boundaries agreed by the PDG. • Any useful evidence that could inform the parameters of the model to be forwarded to the NICE team. • Nick Wareham to send Alan Brennan some references to recent research on physical activity and CVD. 	<p>PDG to send to the NICE team</p> <p>Nick Wareham</p>
<p>5. SchARR evidence review (Emma Everson Hock)</p>	<p>Emma Everson Hock from SchARR presented the findings from the third evidence review entitled 'Awareness-raising in health professionals and high risk group identification'.</p> <p>The PDG were given an opportunity to ask any questions or make any comments on the review.</p> <p>Action points:</p> <ul style="list-style-type: none"> • The PDG to send any other relevant papers to the SchARR team for inclusion in the final report. • SchARR to consider some of the grey literature available on this topic and PDG members to send any relevant web links. 	<p>PDG</p> <p>SchARR/ PDG</p>
<p>6. Draft recommendations and considerations (All)</p>	<p>Clare Wohlgemuth outlined the process for developing recommendations.</p> <p>The PDG divided into 2 groups to draft recommendations and considerations based on review 3 and the expert testimony heard during the morning. Revisions to the recommendations developed in previous meetings were put back to the next PDG meeting.</p> <p>Each group considered the following:</p> <p>Whose health will benefit? Who should take action? What action should be taken?</p>	
<p>7. Feedback from Groups</p>	<p>Each group presented their draft recommendations and considerations for discussion.</p> <p>The NICE team collected notes from each group.</p> <p>Action point: The NICE team will transcribe the recommendations and considerations into a word document. At the next meeting the recommendations from today's meeting and previous meetings will be considered.</p>	<p>NICE team</p>
<p>8. Health econom-</p>	<p>Nick Wareham summarised what has been agreed in terms of developing the economic model, and which interventions</p>	

ics: a way forward (Nick Wareham)	should be included.	
9. AOB	Any additions to the glossary should be sent to the NICE team.	PDG
Close	The meeting closed at 4.30pm.	

Date of next meeting: 30th June 2010, Derwent, NICE offices, Mid City Place, 71 High Holborn, London, WC1V 6NA